Peritoneal dialysis (PD) is an effective home-based therapy for end-stage renal failure. Intraperitoneal administration of drugs to PD patients is particularly important for the treatment of peritonitis. Clinicians need to know that the administered drug is compatible with both the PD solution and its container. A detailed literature search on drug compatibility and stability was performed and results of all published stability studies are presented for all drugs, PD solutions, and containers studied. These data will aid clinicians managing PD patients and provide a resource to demonstrate which drugs have been shown to be stable in various PD solutions and solution containers. This is important information to assist clinicians in applying effective treatments, in particular, for peritonitis.
HamadaC., HayashiK., ShouI., InabaM., RoY., IoH.Pharmacokinetics of calcitriol and maxacalcitol administered into peritoneal dialysate bags in peritoneal dialysis patients.Perit Dial Int2005; 25(6): 570–5.
10.
ThomaeU., KoblingerS.[Transperitoneal resorption of cefotiam in CAPD patients with and without peritonitis] [in German].Med Klin (Munich)1994; 89(9): 464–8.
11.
de FijterC.W., ter WeeP.M., OeL.P., VerbrughH.A.Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (C)APD-related peritonitis: a prospective randomized multicenter comparison (CIPPER trial).Perit Dial Int2001; 21(5): 480–6.
12.
BoeschotenE.W., RietraP.J., KredietR.T., VisserM.J., AriszL.CAPD peritonitis: a prospective randomized trial of oral versus intraperitoneal treatment with cephradine.J Antimicrob Chemother1985; 16(6): 789–97.
13.
BrouardR., TozerT.N., MerdjanH., GuilleminA., BaumelouA.Transperitoneal movement and pharmacokinetics of cefotiam and cefsulodin in patients on continuous ambulatory peritoneal dialysis.Clin Nephrol1988; 30(4): 197–206.
RusthovenE., van de KarN.C., MonnensL.A., SchroderC.H.Long-term effectiveness of intraperitoneal erythropoietin in children on NIPD by administration in small bags.Perit Dial Int2001; 21(2): 196–7.
17.
DahlN.V., FooteE.F., SearsonK.M., FeinJ.L., KapoianT., StewardC.A.Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis.Ann Pharmacother1998; 32(12): 1284–9.
18.
LuiS.F., ChengA.B., LeungC.B., WongK.C., LiP.K., LaiK.N.Imipenem/cilastatin sodium in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis.Am J Nephrol1994; 14(3): 182–6.
19.
AlbinH., RagnaudJ.M., Demotes-MainardF., VinconG., WoneC.Pharmacokinetics of intravenous and intraperitoneal moxalactam in chronic ambulatory peritoneal dialysis.Eur J Clin Pharmacol1986; 30(3): 299–302.
20.
GilbertT.B., JacobsS.C., QuaddouraA.A.Deafness and prolonged neuromuscular blockade following single-dose peritoneal neomycin irrigation.Can J Anaesth1998; 45(6): 568–70.
21.
PlumJ., ArtikS., BuschT., SahinK., GrabenseeB.Oral versus intraperitoneal application of clindamycin in tunnel infections: a prospective, randomized study in CAPD patients.Perit Dial Int1997; 17(5): 486–92.
22.
SchmitJ.L., HaryL., BouP., RenaudH., WesteelP.F., AndrejakM.Pharmacokinetics of single-dose intravenous, oral, and intraperitoneal pefloxacin in patients on chronic ambulatory peritoneal dialysis.Antimicrob Agents Chemother1991; 35(7): 1492–4.
23.
The United States Pharmacopeia.25th ed.Rockville, MD: United States Pharmacopeial Convention; 2002.
24.
TrisselL.A.Handbook on Injectable Drugs.13th ed.Bethesda, MD: American Society of Health-System Pharmacists; 2005.
25.
ArsèneM., FavettaP., FavierB., BureauJ.Comparison of ceftazidime degradation in glass bottles and plastic bags under various conditions.J Clin Pharm Ther2002; 27(3): 205–9.
26.
QuellhorstE.Insulin therapy during peritoneal dialysis: pros and cons of various forms of administration.J Am Soc Nephrol2002; 13(Suppl 1): S92–6.
27.
NevalainenP., LahtelaJ.T., MustonenJ., PasternackA.The influence of peritoneal dialysis and the use of subcutaneous and intraperitoneal insulin on glucose metabolism and serum lipids in type 1 diabetic patients.Nephrol Dial Transplant1997; 12(1): 145–50.
28.
WilliamsP., MariottJ., ColesG., SteadR., TranaeusA., HopwoodA.M.Insulin efficacy with a new bicarbonate/lactate peritoneal dialysis solution.Perit Dial Int2000; 20(4): 467–9.
29.
JohnsonC.A., AmidonG., ReichertJ.E., PorterW.R.Adsorption of insulin to the surface of peritoneal dialysis solution containers.Am J Kidney Dis1983; 3(3): 224–8.
30.
VogesM., Divino-FilhoJ.C., FaictD., SomersF., VermeulenP.Compatibility of insulin over 24 hours in standard and bicarbonate-based peritoneal dialysis solutions contained in bags made of different materials.Perit Dial Int2006; 26(4): 498–502.
31.
BrangeJ., LangkjaerL.Chemical stability of insulin. 3. Influence of excipients, formulation, and pH.Acta Pharm Nord1992; 4(3): 149–58.
32.
GriseG., LemelandJ.F., FillastreJ.P.[Stability of 8 second or third generation cephalosporins in peritoneal dialysis fluid] [in French].Pathol Biol (Paris)1985; 33(5): 335–9.
33.
QuentinC., BouchetJ.J., GaillardI., BebearC.Stability of fosfomycin and quinolones in peritoneal dialysis solution.J Antimicrob Chemother1990; 25(5): 878–80.
34.
HalsteadD.C., GuzzoJ., GiardinaJ.A., GeshanA.E.In vitro bactericidal activities of gentamicin, cefazolin, and imipenem in peritoneal dialysis fluids.Antimicrob Agents Chemother1989; 33(9): 1553–6.
35.
SewellD.L., GolperT.A.Stability of antimicrobial agents in peritoneal dialysate.Antimicrob Agents Chemother1982; 21(3): 528–9.
36.
SewellD.L., GolperT.A., BrownS.D., NelsonE., KnowerM., KimbroughR.C.Stability of single and combination antimicrobial agents in various peritoneal dialysates in the presence of insulin and heparin.Am J Kidney Dis1983; 3(3): 209–12.
37.
DrakeJ.M., MyreS.A., StaneckJ.L., DraegerR.W.Antimicrobial activity of vancomycin, gentamicin, and tobramycin in peritoneal dialysis solution.Am J Hosp Pharm1990; 47(7): 1604–6.
38.
PaapC.M., NahataM.C.Stability of cefotaxime in two peritoneal dialysis solutions.Am J Hosp Pharm1990; 47(1): 147–50.
39.
TrisselL.A.Avoiding common flaws in stability and compatibility studies of injectable drugs.Am J Hosp Pharm1983; 40(7): 1159–60.
40.
TrisselL.A., FloraK.P.Stability studies: five years later.Am J Hosp Pharm1988; 45(7): 1569–71.
41.
DooleyD.P., TylerJ.R., WorthamW.G., HarrisonL.S., StarnesW.F.Jr., CollinsG.R.Prolonged stability of antimicrobial activity in peritoneal dialysis solutions.Perit Dial Int2003; 23(1): 58–62.
42.
ParkS.E., TwardowskiZ.J., MooreH.L.Stability of iron concentrations in peritoneal dialysis solution bags.Perit Dial Int1997; 17(2): 210–11.
43.
JanknegtR., PaulissenA., HooymansP.M., LohmanJ.J., HermensW.A.Stability of amphotericin B in CAPD fluid.Perit Dial Int1990; 10(4): 287–9.
44.
VogesM., FaictD., LechienG., TaminneM.Stability of drug additives in peritoneal dialysis solutions in a new container.Perit Dial Int2004; 24(6): 590–5.
45.
Fernández-VarónE., MarínP., EspunyA., VillamayorL., EscuderoE., CárcelesC.Stability of moxifloxacin injection in peritoneal dialysis solution bags (Dianeal PD1 1.36% and Dianeal PD1 3.86%).J Clin Pharm Ther2006; 31(6): 641–3.
46.
NornooA.O., ElwellR.J.Stability of vancomycin in icodextrin peritoneal dialysis solution.Ann Pharmacother2006; 40(11): 1950–4.
47.
RobinsonR.F., MoroscoR.S., SmithC.V., MahanJ.D.Stability of cefazolin sodium in four heparinized and non-heparinized dialysate solutions at 38°C.Perit Dial Int2006; 26(5): 593–7.
48.
ElwellR.J., VolinoL.R., FryeR.F.Stability of cefepime in icodextrin peritoneal dialysis solution.Ann Pharmacother2004; 38(12): 2041–4.
49.
LinY.F., WuC.C., LinS.H., WangD.P., WangC.N.Stability of cefazolin sodium in icodextrin-containing peritoneal dialysis solution.Am J Health Syst Pharm2002; 59(23): 2362, 2364.
50.
WuC.C., WangD.P., WongC.Y., LinY.F.Stability of cefazolin in heparinized and nonheparinized peritoneal dialysis solutions.Am J Health Syst Pharm2002; 59(16): 1537–8.
51.
StamatakisM.K., LeaderW.G., TracyT.S.Stability ofhigh-dose vancomycin and ceftazidime in peritoneal dialysis solutions.Am J Health Syst Pharm1999; 56(3): 246–8.
52.
ManduruM., FarielloA., WhiteR.L., FoxJ.L., BossoJ.A.Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution.Am J Health Syst Pharm1996; 53(22): 2731–4.
53.
ParkT.W., Le-BuiL.P., ChungK.C., RhoJ.P., GillM.A.Stability of piperacillin sodium-tazobactam sodium in peritoneal dialysis solutions.Am J Health Syst Pharm1995; 52(18): 2022–4.
54.
VaughanL.M., PoonC.Y.Stability of ceftazidime and vancomycin alone and in combination in heparinized and nonheparinized peritoneal dialysis solution.Ann Pharmacother1994; 28(5): 572–6.
55.
KaneM.P., BailieG.R., MoonD.G., SiuI.Stability of ciprofloxacin injection in peritoneal dialysis solutions.Am J Hosp Pharm1994; 51(3): 373–7.
56.
HolmesS.E., AldousS.Stability of cotrimoxazole in peritoneal dialysis fluid.Perit Dial Int1990; 10(2): 157–60.
57.
HolmesS.E., AldousS.Stability of miconazole in peritoneal dialysis fluid.Am J Hosp Pharm1991; 48(2): 286–90.
58.
ManleyH.J., GrabeD.W., NorcrossM., CoopermanT.A., StinchcombA.L., HassM.Stability of amphotericin B-lipid complex (Abelcet) in peritoneal dialysis solutions.Perit Dial Int2000; 20(1): 87–90.
59.
NahataM.C., AhaltP.A.Stability of cefazolin sodium in peritoneal dialysis solutions.Am J Hosp Pharm1991; 48(2): 291–2.
60.
WalkerP.C., KaufmannR.E., MassoudN.Compatibility of cefazolin and gentamicin in peritoneal dialysis solutions.Drug Intell Clin Pharm1986; 20(9): 697–700.
61.
WilliamsonJ.C., VollesD.F., LynchP.L., RogersP.D., HaverstickD.M.Stability of cefepime in peritoneal dialysis solution.Ann Pharmacother1999; 33(9): 906–9.
62.
NahataM.C.Stability of ceftriaxone sodium in peritoneal dialysis solutions.DICP1991; 25(7-8): 741–2.
63.
MawhinneyW.M., AdairC.G., GormanS.P., McClurgB.Stability of ciprofloxacin in peritoneal dialysis solution.Am J Hosp Pharm1992; 49(12): 2956–9.
64.
KehoeW.A., WeberJ.N., FriesD.S.The stability and compatibility of clindamycin phosphate and gentamicin sulfate alone and in combination in peritoneal dialysis solution.Perit Dial Int1988; 8(2): 153–4.
CookerL.A., LuneburgP., FaictD., ChooC., HolmesC.J.Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags.Perit Dial Int1997; 17(4): 373–8.
74.
ZhouM., NotariR.E.Influence of pH, temperature, and buffers on the kinetics of ceftazidime degradation in aqueous solutions.J Pharm Sci1995; 84(5): 534–8.
75.
MasonN.A., JohnsonC.E., O'BrienM.A.Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution.Am J Hosp Pharm1992; 49(5): 1139–42.
76.
WaznyL.D., BlakeP.G.Incompatibility of vancomycin and ceftazidime for intraperitoneal use.Perit Dial Int2002; 22(1): 93–4.
77.
FarchioneL.A.Inactivation of aminoglycosides by penicillins.J Antimicrob Chemother1981; 8(Suppl A): 27–36.
